0001615774-18-001760.txt : 20180309 0001615774-18-001760.hdr.sgml : 20180309 20180309160141 ACCESSION NUMBER: 0001615774-18-001760 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180307 FILED AS OF DATE: 20180309 DATE AS OF CHANGE: 20180309 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Vivo Capital VIII, LLC CENTRAL INDEX KEY: 0001618789 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37411 FILM NUMBER: 18680050 BUSINESS ADDRESS: STREET 1: 505 HAMILTON AVENUE, SUITE 200 CITY: PALO ALTO STATE: CA ZIP: 94301 BUSINESS PHONE: 650 688 0822 MAIL ADDRESS: STREET 1: 505 HAMILTON AVENUE, SUITE 200 CITY: PALO ALTO STATE: CA ZIP: 94301 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BioPharmX Corp CENTRAL INDEX KEY: 0001504167 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 593843182 STATE OF INCORPORATION: DE FISCAL YEAR END: 0131 BUSINESS ADDRESS: STREET 1: 1505 ADAMS DRIVE, SUITE D CITY: MENLO PARK STATE: CA ZIP: 94025 BUSINESS PHONE: 650-889-5020 MAIL ADDRESS: STREET 1: 1505 ADAMS DRIVE, SUITE D CITY: MENLO PARK STATE: CA ZIP: 94025 FORMER COMPANY: FORMER CONFORMED NAME: THOMPSON DESIGNS INC DATE OF NAME CHANGE: 20101022 4 1 s109293_form4.xml 4 X0306 4 2018-03-07 0 0001504167 BioPharmX Corp BPMX 0001618789 Vivo Capital VIII, LLC 505 HAMILTON AVENUE, SUITE 207 PALO ALTO CA 94301 0 0 1 0 Common Stock 2018-03-07 4 S 0 2000000 0.36 D 16128515 I See Footnote These shares are owned directly by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P., which are the record owners of these shares. Vivo Capital VIII, LLC is the general partner of both Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. and may be deemed to beneficially own such shares. The voting members of Vivo Capital VIII, LLC are Frank Kung, Albert Cha, Edgar Engleman, Chen Yu, and Shan Fu, none of whom has individual voting or investment power with respect to these shares and each of whom disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.33 to $0.37, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. /s/ Albert Cha, Managing Member of Vivo Capital VIII, LLC 2018-03-09